ReviewFrontiers in immunology2026
iPSC-derived CAR-NK extracellular vesicles for non-small cell lung cancer: evidence, engineering, and translational barriers.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) remains difficult to treat with adoptive cell therapies because of antigen heterogeneity, immunosuppressive tumor microenvironments, stromal barriers, and manufacturing variability. Direct evidence for iPSC-derived CAR-NK EV/sEV therapy in NSCLC is currently unavailable. Accordingly, this narrative review evaluates the platform as a translational hypothesis by integrating mechanistic evidence from CAR-engineered EV studies, biological-analog evidence from NK-cell EVs and other engineered EV systems, and clinical-analog evidence from living iPSC-NK or CAR-NK products. The proposed platform could combine a renewable producer-cell source, antigen-directed vesicle binding, and cytotoxic cargo delivery; however, each component, and particularly their integration into a single reproducible product, requires direct experimental validation. Compared with living cell products, CAR-NK sEVs may reduce selected risks related to cellular expansion, persistence, graft-versus-host disease, cytokine release syndrome, and neurotoxicity; however, they do not inherently eliminate antigen-dependent on-target/off-tumor toxicity. Their nanoscale size is hypothesized to improve access to selected stromal barriers in preclinical models, but human solid-tumor penetration remains unproven. Major unresolved issues include rapid systemic clearance and sequestration by hepatic and splenic components of the mononuclear phagocyte system, route-dependent pulmonary deposition, mucus and mucociliary clearance, pulmonary macrophage uptake, subtype- and lesion-specific antigen heterogeneity, EV identity and purity, CAR-positive vesicle quantification, potency-adjusted manufacturing yield, lot comparability, and the absence of potency assays validated across laboratories or linked to clinical outcomes. Thus, iPSC-CAR-NK sEVs should currently be viewed as an investigational translational concept rather than a clinically ready NSCLC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.